In this prespecified exploratory analysis from INTRIGUE, we present the landscape of KIT mutations at the onset of imatinib failure and evaluate the efficacy of ripretinib versus sunitinib in patients with advanced GIST according to baseline KIT mutation status as determined by ctDNA analysis. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.